What is Pinealon? What it does, benefits and what the evidence shows

Pinealon is a synthetic tripeptide, Glu-Asp-Arg (also written EDR), promoted for memory and brain ageing. We found no approval for it (where we looked is below), and nearly all of the research behind it comes from one Russian research group, the one that also developed Epitalon. That work is in cultured cells and rodents; the only human reports we found are two small Russian-language studies whose abstracts describe no placebo group. The one independent test we found, a 2026 mouse preprint, saw a trend toward better working memory that was not significant.

What Pinealon is and how it works

Pinealon is the tripeptide Glu-Asp-Arg, the "EDR peptide" in the research literature. A 2011 cell study of Pinealon came from the Saint Petersburg Institute of Bioregulation and Gerontology, where Vladimir Khavinson is based (Khavinson et al., Rejuvenation Research, 2011). The same institute is behind the Epitalon research, and a 2024 paper from institute authors tested EDR side by side with the four-amino-acid peptide Ala-Glu-Asp-Gly, which is Epitalon's sequence (Kraskovskaya et al., International Journal of Molecular Sciences, 2024).

How it might work is a proposal, not a finding. In rat cerebellar neurons and other cells, Pinealon reduced the build-up of reactive oxygen species and cell death under oxidative stress, and the authors concluded that besides antioxidant activity it may "interact directly with the cell genome" (Khavinson et al., 2011). A later review from the same group says the peptide is assumed to enter cells and bind to histone proteins or RNA, which would change the activity of genes involved in cell survival and antioxidant defense (Khavinson et al., Molecules, 2020). "Is assumed" is the review's own wording, and we found no independent confirmation of that mechanism.

A note on where the evidence comes from

Read every result below with this in mind. Most Pinealon papers we found list Khavinson or an institute colleague among the authors, including the 2011 cell study, the 2012 rat study, the 2020 review, the 2021 mouse study and a 2024 cell study. Our search covered PubMed and Europe PMC for "pinealon", "EDR peptide" and "Glu-Asp-Arg". Work from a single group is not automatically wrong, but it has not been checked by anyone without a stake in the original claims. The same caveat applies to Epitalon, and our Epitalon guide covers it in more depth.

What people use it for

What the research actually shows

Cells and rodents

In the 2011 cell study, Pinealon limited the accumulation of reactive oxygen species in cerebellar granule cells, neutrophils and PC12 cells, and reduced necrotic cell death (Khavinson et al., 2011). In a 2012 rat study, giving Pinealon to pregnant rats on a high-methionine diet, which raises homocysteine, improved the offspring's spatial orientation and learning and made their cerebellar neurons more resistant to oxidative stress (Arutjunyan et al., International Journal of Clinical and Experimental Medicine, 2012). A 2015 study in 18-month-old rats under low oxygen and cold stress compared Pinealon with Cortexin, a polypeptide preparation, and found Cortexin had the stronger effect on free-radical processes and caspase-3 activity in brain (Mendzheritsky et al., Advances in Gerontology, 2015).

In a mouse model of Alzheimer's disease (5xFAD), the EDR peptide and a second tripeptide prevented loss of dendritic spines, the small contact points between neurons (Khavinson et al., 2021). Two cautions apply. The paper's computer-docking work on how the peptide might bind DNA is modelling, not a measured mechanism. And in January 2025 the journal published a correction saying that two of the paper's figures were the same image described differently; the authors said the scientific conclusions were unaffected (correction notice, Pharmaceuticals, 2025). A 2024 study in neurons derived from elderly donors' skin cells found that EDR partly protected against age-related changes, reducing oxidative DNA damage, while having no effect on mitochondrial or lysosomal activity (Kraskovskaya et al., International Journal of Molecular Sciences, 2024).

The independent mouse test

The only outside test we found is a 2026 preprint, meaning it has not been peer reviewed. Over an eight-week period it put five candidate longevity treatments through a short battery of tests in 7-month-old male mice, with five mice per group. Pinealon "showed a trend toward improved working memory without detectable adverse effects" (Marín-Jerez et al., bioRxiv, 2026). The full text calls the effect non-significant and says the small sample and young age of the mice may explain it. It is worth knowing how the study was paid for: the funding statement credits token communities on a research-crowdfunding platform, one of which is listed as $PNL, the same abbreviation the paper uses for its Pinealon group, and a coauthor who directs that platform declares a competing interest. Treat it as a small, early, non-confirming result, not a replication.

Human reports

We found two small human reports, both in Russian with English abstracts. In 32 people aged 41 to 83 with several chronic conditions and a brain syndrome in remission, Pinealon and a second short peptide (Vesugen) were reported to have an anabolic effect and to slow the rate of ageing by biological-age measures. The same abstract reports pro-oxidant activity on a chemiluminescence test and a drop in a marker of blood stem cells (CD34+) that the authors read as significant inhibition of blood cell formation, which they say should be studied further (Meshchaninov et al., 2015). In a study of professional truck drivers, bioregulating peptides, with the best effect from Pinealon combined with a second peptide, were reported to improve psychoemotional measures (Bashkireva and Artamonova, 2012). Neither abstract describes a placebo group, and the second tested a combination, so neither can isolate what Pinealon does.

The group's own 2020 review states that the peptide "improves memory issues in elderly patients" (Khavinson et al., 2020). We could not tie that sentence to a specific controlled trial and did not find one in PubMed or Europe PMC.

Side effects and risks

• No formal human safety data. We found no toxicology or long-term safety study of Pinealon in people. The "no detectable adverse effects" line above is from eight weeks in five mice.
• The one human safety-relevant signal is unresolved. The 32-person report described pro-oxidant activity and a lower blood stem-cell marker. It was small, we found no follow-up, and the abstract does not say whether it had a control group.
• Approval status. A DailyMed search for "pinealon" returned no labels, and Pinealon does not appear in any of the three categories on FDA's list of bulk drug substances nominated for compounding (updated May 14, 2026). The FDA advisory committee's July 2026 peptide vote covered BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax, not Pinealon (NCPA report, July 31, 2026). We did not check other regulators such as the European Medicines Agency. Absence from those lists does not measure safety; it means FDA has not evaluated it there.
• Unknown, not shown harmful. Because the proposed mechanism involves gene activity, whether long-term use does anything unintended is an open question nobody has studied.

What the lab tests show

As of September 29, 2026, VendorVerify's database has 2 Pinealon vials from 2 vendors, with lab reports from April 2025 and September 2025. Purity was 99.84% and 99.87%, and both vials measured 10% to 14% over their label. Neither failed under our definition (empty, under 95% pure, more than 20% under label, or more than 50% over). Two vials tell you nothing about vendors in general, and both are more than a year old.

Because we don't have enough lab data on this compound to rank vendors for it, here are the highest-ranked vendors across all compounds right now. A vendor's overall record is a signal, not a guarantee for a compound they have never had tested.

Buying smarter

Look at each vendor's full record and how many reports sit behind the score, and check the Pinealon results page for new reports. With two aging reports, paying for identity, purity and quantity testing on your own vial is worth it; how to get a peptide tested walks through it, and how to read a peptide COA and fake peptide COAs cover what to check on a report you did not commission. Both vials above came in over label, so it is worth reading how fill amounts drift.

If a report comes back with a fail, stop using that batch, tell anyone who bought from the same run, bring the report to the vendor, and submit it to VendorVerify. Buyers researching brain-focused peptides also read about Epitalon and Semax; the peptide hub lists every compound we track.

Database figures are from VendorVerify as of September 29, 2026. This isn't medical advice; Pinealon has no approval that we could find and its evidence is animal and lab work from one research group.